Abstract:Tumor metastasis has become a fatal disease progress which greatly influence cancer treatment and prognosis. Generally, the metastatic progression can be classified into three main processes: the cancer cells leave the original “tumor home”, travel through “vessel highway”, and settle down in a new “tissue house”. Many agents with various machnisms have been developed for the treatment of cancer cell metastasis, including VEGFR inhibitors, integrin inhibitors, or MMP (matrix metallo protease) inhibitors. Recently a growing interest has been shown for the CXC chemokine receptor 2 (CXCR2), due to their involvement in metastasis physiology. Once CXCR2 is triggered by upstream effectors, it can cause the activation of downstream signals such as serine/threonine kinases, tyrosine kinases. Its essential role in influencing tumor microenvironment makes CXCR2 an important target for anti-tumor metastasis treatment. The first non-peptide CXCR2 antagonist SB225002 was discovered in the mid-1990s by GSK Company. To date, four drug candidates are in clinical trials, including Danirixin, AZD5069, Reparixin and Ladarixin. The clinical indications of AZD5069 were expanded to metastatic head & neck cancer and metastatic pancreatic cancer, in combination with MEDI4736 (a PDL-1 inhibitor). As an excellent computational tool, the pharmacophore model, has been rapidly developed for the identification of novel hit/lead compounds for various targets, especially for proteins without crystal structures. An extensive effort has been made in the attempt to apply pharmacophore model to identify novel VEGFR inhibitors, MMP inhibitors as anti-cancer metastasis agents, revealing that ligand-based pharmacophore model is the best approach when the target geometry is not available, or the binding mode is not elucidated. At present, the binding mode of CXCR2 with its antagonists has not been fully discovered, however, the group of N. Neamati have been trying to establishing a ligand-based pharmacophore model which could be applied for virtual screening to find novel scaffolds of CXCR2 antagonist; this work, for the first time, indicated the feasibility of applying pharmacophore model for the discovery of CXCR2 antagonist. Although a bunch of CXCR2 antagonists have been identified, the anti-tumor metastasis effect of CXCR2 antagonists is not considered in most cases. In our study, a convenient pharmacophore model was built with HipHop program, by screening a mini-database contained compounds which were designed based on the known structure-activity relationship (SAR) of the diarylurea series CXCR2 antagonists. Several novel skeletons with moderate to potent CXCR2 antigonitic activiites were identified. Following optimization resulted in the discovery of compound D45 which showed not only potent CXCR2 antagonist activity with an IC50 value of 10 nM and 910-fold selectivity against CXCR1, but also good in vitro anti-tumor metastatic effect in wound healing assay. Moreover, compound D45 exhibitored promising druglikeness with more than 90% bioavailability in rat. Citation Format: Wen-Hai Huang, Zhi-Long Wang, Jin-Xin Che, Hai-Chao Sheng, Feng Huang, Yong-Zhou Hu, You-Hong Hu, Xin Xie, Xiao-Wu Dong. The discovery of novel small molecular CXCR2 antagonist by using ligand-based pharmacophore model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-064.

Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine As a WSB1 Degrader to Inhibit Cancer Cell Metastasis

Ligand-based pharmacophore model for the discovery of novel CXCR2 antagonists as anti-cancer metastatic agents.

Identification of Potential WSB1 Inhibitors by AlphaFold Modeling, Virtual Screening, and Molecular Dynamics Simulation Studies

Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy

Abstract LB-064: The discovery of novel small molecular CXCR2 antagonist by using ligand-based pharmacophore model

Development of a Novel, Potent, and Selective Sialyltransferase Inhibitor for Suppressing Cancer Metastasis

Small-molecule inhibitors that disrupt the MTDH–SND1 complex suppress breast cancer progression and metastasis

Discovery and Characterization of a Potent Wnt and Hedgehog Signaling Pathways Dual Inhibitor.

Identification of 1,4-Benzodiazepine-2,5-dione Derivatives As Potential Protein Synthesis Inhibitors with Highly Potent Anticancer Activity.

Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation

Identification and biological evaluation of fused tetrahydroisoquinoline derivatives as Wnt/β-catenin signaling inhibitors to suppress colorectal cancer

Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities Against Tumor Growth and Metastasis

Precision Therapeutic Targeting of Human Cancer Cell Motility

Discovery of 1,5-Dihydro-4<i>H</i>-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2

Discovery of thiophen-2-ylmethylene bis-dimedone derivatives as novel WRN inhibitors for treating cancers with microsatellite instability

Discovery of 2-(isoxazol-5-yl)phenyl 3,4-dihydroxybenzoate as a potential inhibitor for the Wnt/β-catenin pathway

Discovery of Novel Aryl Carboxamide Derivatives As Hypoxia-Inducible Factor 1α Signaling Inhibitors with Potent Activities of Anticancer Metastasis.

SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway

Discovery of Potential WEE1 Inhibitors Via Hybrid Virtual Screening

Subtle Structural Alteration in Indisulam Switches the Molecular Mechanisms for the Inhibitory Effect on the Migration of Gastric Cancer Cells

Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer